We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Iscar for Supplemental Care in Stage IV Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00079794
Recruitment Status : Completed
First Posted : March 16, 2004
Last Update Posted : January 25, 2008
Information provided by:

Study Description
Brief Summary:
The purpose of this study it to determine whether supplemental treatment with Iscar improves immune function and quality of life among Stage IV non-small cell lung carcinoma patients receiving conventional chemotherapy. Iscar is an herbal medicine made from the total plant extract of mistletoe. this preparation is already in use in Europe and its use in the US is likely to increase as cancer patients continue to seek alternative therapies.

Condition or disease Intervention/treatment Phase
Lung Cancer Drug: Iscar Drug: mistletoe Phase 2

Detailed Description:
See Brief Summary

Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 36 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Iscar for Supplemental Care in Stage IV Lung Cancer
Study Start Date : September 2001
Primary Completion Date : February 2004
Study Completion Date : February 2004

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer
U.S. FDA Resources

Arms and Interventions

Outcome Measures

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Stage IV NSCLC patients who receive standard chemotherapy

Exclusion criteria:

  • Known allergy to Viscum Album L.
  • Concomitant use of other mistletoe products
  • Concomitant use of mushroom glucan and proteoglycan extracts
  • Concomitant use of thymus extract products
  • Inability to self-report quality of life utilizing assessment tools
  • Ongoing steroid or ACTH therapy
  • Co-morbid immunocompromised state
  • Pregnancy
  • Participation in other clinical trials
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00079794

United States, Pennsylvania
Thomas Jefferson University
Philadelphia, Pennsylvania, United States, 19107
Sponsors and Collaborators
National Center for Complementary and Integrative Health (NCCIH)
Principal Investigator: Steven Rosenzweig, MD Jefferson Medical College of Thomas Jefferson University
More Information

ClinicalTrials.gov Identifier: NCT00079794     History of Changes
Other Study ID Numbers: R21AT001020-01 ( U.S. NIH Grant/Contract )
First Posted: March 16, 2004    Key Record Dates
Last Update Posted: January 25, 2008
Last Verified: January 2008

Keywords provided by National Center for Complementary and Integrative Health (NCCIH):
lung cancer
herbal medicine
non-small cell cancer

Additional relevant MeSH terms:
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases